America of a famous hospital Scientists by Cancer A cell-killing drug has been developed that destroys solid tumors through ‘targeted chemotherapy‘.
The pill contains a protein, for example, that acts like a ‘blizzard that can shut down an airline’s main hub and thus stop the flow of only planes carrying cancer cells.’
The protein was developed by a research team at City of Hope Hospital, one of the largest cancer research and treatment organizations in the United States.
A molecule called AOH1996 works by targeting the cancer variant of PCNA, a protein important for DNA replication and tumor growth.
Developed over the past two decades, this drug has proven effective in clinical research to treat breast, prostate, brain, ovarian, cervical, skin and lung cancers.
In this study, published in the medical journal ‘Cell Chemical Biology’, this protein was tested on more than 70 cancer cell lines.
This section contains related reference points (Related Nodes field).
The results showed that the AOH1996 molecule selectively killed cancer cells by disrupting the normal reproductive cycle of the cell. The next step is to advance these findings through clinical trials in humans.
Dr Linda Malkas, PhD, Professor of Molecular Diagnostics and Experimental Therapeutics at City of Hope and MT&BA Professor of Molecular Oncology, Ahmadineja said: ‘PCNA is like a large airline terminal hub with a More air gates are included. The data showed that PCNA is uniquely mutated in cancer cells and this fact helped us develop a drug that would target only the mutated form of PCNA in cancer cells. is.’
He added: ‘Our cancer-killing drug is like a blizzard that shuts down a major airline hub only to stop all flights carrying cancer cells.’
According to him: ‘The results have been promising. AOH1996 can inhibit tumor growth as a monotherapy without inducing toxicity in cell and animal models. The investigational chemotherapy is currently in a phase one human clinical trial at City of Hope.’
The study’s lead author, Long Guo, associate research professor in the Department of Molecular Diagnostics at Beckman Research Institute in the City of Hope, added: ‘No drug has ever targeted PCNA therapeutically. was made because it was considered ‘untreatable’ but clearly City of Hope was able to develop an investigational drug to target a challenging protein.’
According to him: ‘We discovered that PCNA is one of the possible causes of increased nucleic acid replication errors in cancer cells. Now that we know the specific part of the problem and can prevent it, we will go deeper to understand the process to develop more personalized and targeted cancer drugs.’
#Breakthrough #cancer #treatment #tumorkilling #drug #discovered
What are the main benefits of AOH1996 compared to traditional chemotherapy treatments?
**Interview with Dr. Linda Malkas on the Innovative Cancer Treatment Breakthrough at City of Hope Hospital**
**Editor**: Thank you, Dr. Malkas, for joining us today. You and your team at City of Hope Hospital have developed a new drug, AOH1996, that appears to be a significant advancement in cancer treatment. Can you tell us more about how this drug works?
**Dr. Malkas**: Thank you for having me. AOH1996 functions as a targeted chemotherapy agent designed to specifically attack cancer cells. Think of it as a blizzard that halts an airline’s operations. Our drug essentially shuts down the ‘hub’ where cancer cells thrive by targeting a mutated variant of the PCNA protein essential for DNA replication and tumor growth.
**Editor**: That sounds groundbreaking. What types of cancers has this drug shown promise in treating?
**Dr. Malkas**: In our studies, AOH1996 has proven effective against multiple cancer types, including breast, prostate, brain, ovarian, cervical, skin, and lung cancers. We have conducted extensive testing on more than 70 different cancer cell lines, which has demonstrated its selectivity in killing cancerous cells while sparing healthy ones.
**Editor**: The study was recently published in ‘Cell Chemical Biology.’ What are the next steps for your research?
**Dr. Malkas**: After the promising results in preclinical research, our next step is to advance AOH1996 into clinical trials in humans. This phase will be critical for assessing its efficacy and safety in patients, and we are hopeful about what those trials will reveal.
**Editor**: Encouraging news indeed! What do you believe sets this treatment apart from other existing cancer therapies?
**Dr. Malkas**: The unique aspect of AOH1996 is its precision. Traditional chemotherapy can be quite harsh on the body and often affects healthy cells. Our research indicates that AOH1996 can selectively target only the cancerous cells, potentially leading to fewer side effects and improved outcomes for patients.
**Editor**: That’s a significant advantage. How long do you anticipate it might be before patients can access this treatment?
**Dr. Malkas**: While it’s difficult to predict exact timelines, we are aiming to begin clinical trials in the near future. If all goes well, and the trials demonstrate safety and effectiveness, we could see AOH1996 available to patients within a few years.
**Editor**: Thank you, Dr. Malkas, for sharing your insights and the exciting developments from your research. We wish you and your team the best of luck in your future endeavors.
**Dr. Malkas**: Thank you! We’re excited about the potential of AOH1996 to make a difference in the lives of cancer patients.
